ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "lactation and pregnancy"

  • Abstract Number: 1298 • 2017 ACR/ARHP Annual Meeting

    Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

    Tayseer Haroun1, Amanda M. Eudy2,3,4,5, Malithi Jayasundara2, W. Benjamin Nowell6,7, Jeffrey R. Curtis8, Charlotte Whitney White9, Rachelle Crow-Hercher9, Seth D. Ginsberg10 and Megan E. B. Clowse4,11, 1Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 2Rheumatology, Duke University Medical Center, Durham, NC, 3Duke University, Durham, NC, 4Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 5Duke University Medical Center, Chapel Hill, NC, 6CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, 7Global Healthy Living Foundation, Upper Nyack, NY, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Arthritis Power, Upper Nyack, NY, 10Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 11Duke University Medical Center, Durham, NC

    Background/Purpose: With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought…
  • Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting

    Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study

    Megan E. B. Clowse1, Frauke Förger2, Caroline Hwang3, John Thorp4, Radboud J. E. M. Dolhain5, Astrid van Tubergen6, Laura Shaughnessy7, Jeff Simpson8, Marie Teil9, Nathalie Toublanc10, Maggie Wang8 and Thomas W. Hale11, 1Rheumatology, Duke University School of Medicine, Durham, NC, 2Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, 3Keck Hospital of USC, Los Angeles, CA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, 6Maastricht University Medical Center, Maastricht, Netherlands, 78010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, 8UCB Pharma, Raleigh, NC, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Brussels, Belgium, 11Texas Tech University School of Medicine, Amarillo, TX

    Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology